There are currently 1520 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland +7 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/24/2024
Locations: Department of Orthopedic Surgery, Johns Hopkins Outpatient Center, Baltimore, Maryland
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Register for Updates
Multi-analyte Blood Test Clinical Trial
NCT05199259
Recruiting
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: GI Research Mercy Medical Center, Baltimore, Maryland
Conditions: Liver Cirrhosis, Liver Cancer, HCC, Hepatocellular Carcinoma
Register for Updates
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
NCT05457010
Recruiting
The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
T CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS
NCT05141058
Recruiting
This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study a... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
06/04/2024
Locations: The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Conditions: SARS-CoV-2 Infection
Register for Updates
Registry Study for Radiation Therapy Outcomes
NCT01255748
Recruiting
The purpose of this research study is to collect and analyze information from patients being treated with various forms of radiation therapy.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2024
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Neoplasms
Register for Updates
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT01766297
Recruiting
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
05/30/2024
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Register for Updates
Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
NCT04197596
Recruiting
BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).
Gender:
ALL
Ages:
Between 1 month and 79 years
Trial Updated:
05/30/2024
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Viral Infection, Primary Immune Deficiency Disorder
Register for Updates
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
NCT05539196
Recruiting
This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
05/30/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Movement Disorders, Neurology, Parkinsons Disease
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Type2Diabetes, ASCVD
Register for Updates
Vaginal Cuff Brachytherapy Fractionation Study
NCT03785288
Recruiting
The purpose of this study is to see the effects of two different standard of care treatments of endometrial cancer on sexual dysfunction. This study will compare two standard of care treatments: HDR (high dose radiation) vaginal brachytherapy 3 fractions of 7 Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: University of Maryland Medical Center (UMMC), Baltimore, Maryland
Conditions: Endometrial Cancer
Register for Updates
Retraining Reaching in Cerebellar Ataxia
NCT03879018
Recruiting
The purpose of this study is to test for benefits of reinforcement based training paradigm versus standard practice over weeks for improving reaching movements in people with ataxia.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
05/17/2024
Locations: Motion Analysis Lab in the Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Cerebellar Ataxia
Register for Updates